AMP: Access for More Patients Transforms Patient Access to Specialty Medications

September 25, 2019

Technology-driven patient support solution cuts time to therapy by 27 percent and supports ongoing adherence to medication regimens

IRVING, Texas, Sept. 25, 2019RxCrossroads by McKesson and CoverMyMeds today announced the launch of AMP: Access for More Patients™, a first-in-class, technology-driven patient support solution that transforms how patients access, afford and adhere to their medications. Designed to automate access to specialty medications for physicians and patients, this collaboration brings together the robust technology platform and established provider network of CoverMyMeds with the deep specialty experience and commercialization expertise of RxCrossroads by McKesson.

Innovative therapies designed to treat complex and chronic specialty diseases continue to reach the market¹, growing from fewer than 30 specialty medications approved by the FDA in the early 1990s to more than 400 today²,³. The traditional hub model that helps enroll an average of one in five patients into specialty medication access programs has complex requirements and time-consuming manual processes, which, on average, delay treatment by up to eight weeks4.

Fundamentally changing the way patient support is provided, the proprietary AMP solution enables four out of five patients across the United States to access their specialty medications 27 percent faster than traditional hub programs5. By integrating directly into the physician workflow, AMP enables patients to enroll into biopharma-sponsored patient support programs at the point of prescribing, in real-time before the patient leaves the provider’s office. Results published today in an AMP case study found AMP’s ability to capture patient consent in the provider’s office also helped increase patient enrollment completion by 92 percent.5

“Our goal is to be the new starting point for specialty medication access utilizing the industry’s most trusted network, allowing us to positively impact patients from the time the prescription is written and throughout their treatment journey,” said Erica Conroy, VP of Specialty, CoverMyMeds. “As part of this innovative solution, we are bringing biopharma-sponsored hub services into the physician workflow for visibility at a patient case level from diagnosis and therapy initiation to ongoing adherence support.”

AMP also provides high-touch services for patient cases that need intervention support beyond the automated technology platform, such as proactive clinical support, behavioral coaching and financial assistance. These patient-centric programs improve adherence to medication regimens by an average of 10 percent6, helping to support better outcomes for patients. AMP also helps patients manage reimbursement issues, incomplete benefits information, payment denials and appeals, and other exceptions to enable optimal access to medications.

“Biopharma companies provide a broad range of access and adherence services to help patients overcome financial obstacles and remain on therapy. However, one in five patients aren’t aware of these services or know that help is available,” said Meagan Sampogna, VP of Business Transformation, RxCrossroads by McKesson. “AMP enables the opportunity to reach four out of five patients with efficient technology-driven processes and human intervention to drive greater patient adherence and outcomes⁶.”

The AMP case study will be highlighted at CBI’s 13th Hub and SPP Model Optimization in San Diego. Attendees of the conference are invited to attend Erica Conroy’s and Meagan Sampogna’s presentation, “Streamlining Patient Access Through Adaptable Technology: Next Generation in Hub Services,” at 4:35 p.m. PT on September 26 to learn more about AMP.

AMP is currently available for specialty therapies. For more information about AMP, visit and

  1. FAQs from Genetic and Rare Disease Information Center, U.S. Department of Health and Human Services
  2. The Evolution of Specialty Pharmacy
  3. Trends in FDA Approval of Specialty Drugs 1990 through 2017, RJ Health
  4. The Impact of Disease-Modifying Therapy Access Barriers on People with Multiple Sclerosis: Mixed-Methods Study, Journal of Medical Internet Research, 2018
  5. AMP Case Study, 2019
  6. RxCrossroads by McKesson data, 2018

About RxCrossroads by McKesson

RxCrossroads by McKesson creates flexible, connected solutions for life sciences companies. Its solutions focus on increasing access, adherence, and safe use conditions, seamlessly connecting patients to their therapies, and enabling them to thrive at every step in their care journey. Through expert teams, deep market insights and innovative technology, RxCrossroads by McKesson designs forward-thinking solutions that optimize the patient experience and positions its customers for success in every phase of the product life cycle. As part of McKesson Life Sciences, a business within McKesson Corporation, RxCrossroads by McKesson harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

About CoverMyMeds

CoverMyMeds, part of McKesson Prescription Technology Solutions, is one of the fastest growing health care technology companies in the U.S. and consistently recognized as one of the best places to work in the country. CoverMyMeds’ solutions help patients get the medications they need to be healthy by seamlessly connecting the health care network to improve medication access; thereby increasing speed to therapy and reducing prescription abandonment. CoverMyMeds’ network includes more than 500 electronic health record systems (EHRs), 60,000 pharmacies, 700,000 providers and most health plans and PBMs. By facilitating appropriate access to medications, the company can help its customers avoid billions of dollars each year in administrative waste and avoidable medical spending caused by prescription abandonment. Visit for more information.

PR Contact

RxCrossroads by McKesson
Claire Crye, Public Relations
(281) 825-9927

Angela Masciarelli, Public Relations
(614) 360-1735